Molecular Biology Reports

, Volume 45, Issue 3, pp 379–387 | Cite as

Expressions of some antioxidant genes in SH-SY5Y cells treated with β-lapachone, morphine and electromagnetic field

  • Hamideh Mahmoudinasab
  • Mostafa Saadat
Original Article


β-Lapachone (β-Lap), morphine (Mor), and electromagnetic field (EMF) generate reactive oxygen species. The goal of the present study was to examine the effects of Mor and EMF, in combination with β-Lap on the cell growth inhibition and expression of several antioxidant genes. The 0.50 mT intensity of 50 Hz EMF and two exposure conditions (“15 min field-on/15 min field-off” and “30 min field-on continuously”) on SH-SY5Y cells were used. The effects of Mor and EMF, in combination with β-Lap on cell growth inhibition and the expression levels of several antioxidant genes (NQO1, NQO2, SOD1, SOD2, CAT, GSTO1, GSTM2, GSTM3, GSTP1, MGST1, MGST3) in SH-SY5Y cells were measured. The relative mRNA levels were calculated according to the \({{\text{2}}^ - }^{{\Delta \Delta {{\text{C}}_{\text{t}}}}}\). Whereas NQO1 mRNA level decreased in the “15 min field-on/15 min field-off” condition, the expression level of NQO2 was increased. Both NQO1 and NQO2 expressions increased in Mor treated cells. IC50 values of β-Lap in combination with Mor, EMF, and “Mor + EMF” were higher than cells treated only with β-Lap. The NQO1 expression level in the cells treated with β-Lap was higher than the other treatments, indicating that β-Lap induces the expression of NQO1. Moreover, multiple linear regression analysis indicated that NQO1 mRNA levels were associated positively with β-Lap and negatively with EMF. At least in part, the mRNA levels of NQO1 were associated with IC50 values of β-Lap in designed treatments. There is a negative association between mRNA levels of NQO1 and IC50 values of β-Lap but not NQO2.


Extremely low-frequency electromagnetic field Combination therapy NQO1 



This study was supported by Shiraz University, Iran (93GCU2M1741).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.


  1. 1.
    Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA (2000) NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275:5416–5424CrossRefPubMedGoogle Scholar
  2. 2.
    de Witte NV, Stoppani AO, Dubin M (2004) 2-Phenyl-beta-lapachone can affect mitochondrial function by redox cycling mediated oxidation. Arch Biochem Biophys 432:129–135CrossRefPubMedGoogle Scholar
  3. 3.
    Li JZ, Ke Y, Misra HP, Trush MA, Li YR, Zhu H, Jia Z (2014) Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent. Toxicol Appl Pharmacol 281:285–293CrossRefPubMedGoogle Scholar
  4. 4.
    Choi EK, Terai K, Ji IM, Kook YH, Park KH, Oh ET, Griffin RJ, Lim BU, Kim JS, Lee DS, Boothman DA, Loren M, Song CW, Park HJ (2007) Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 9:634–642CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kung HN, Weng TY, Liu YL, Lu KS, Chau YP (2014) Sulindac compounds facilitate the cytotoxicity of beta-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells. PLoS ONE 9:e88122CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Terai K, Dong GZ, Oh ET, Park MT, Gu Y, Song CW, Park HJ (2009) Cisplatin enhances the anticancer effect of beta-lapachone by up-regulating NQO1. Anticancer Drugs 20:901–909CrossRefPubMedGoogle Scholar
  7. 7.
    Celli CM, Tran N, Knox R, Jaiswal AK (2006) NRH: quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 72:366–376CrossRefPubMedGoogle Scholar
  8. 8.
    Long DJ, Jaiswal AK (2000) NRH: quinone oxidoreductase2 (NQO2). Chem Biol Interact 129:99–112CrossRefPubMedGoogle Scholar
  9. 9.
    Lindgren M, Gustavsson M, Hamnerius Y, Galt S (2001) ELF magnetic fields in a city environment. Bioelectromagnetics 22:87–90CrossRefPubMedGoogle Scholar
  10. 10.
    Wolf FI, Torsello A, Tedesco B, Fasanella S, Boninsegna A, D’Ascenzo M, Grassi C, Azzena GB, Cittadini A (2005) 50-Hz extremely low frequency electromagnetic fields enhance cell proliferation and DNA damage: possible involvement of a redox mechanism. Biochim Biophys Acta 1743:120–129CrossRefPubMedGoogle Scholar
  11. 11.
    Zwirska-Korczala K, Jochem J, Adamczyk-Sowa M, Sowa P, Polaniak R, Birkner E, Latocha M, Pilc K, Suchanek R (2005) Effect of extremely low frequency of electromagnetic fields on cell proliferation, antioxidative enzyme activities and lipid peroxidation in 3T3-L1 preadipocytes—an in vitro study. J Physiol Pharmacol 56:101–108PubMedGoogle Scholar
  12. 12.
    Sanie-Jahromi F, Saadat I, Saadat M (2016) Effects of extremely low frequency electromagnetic field and cisplatin on mRNA levels of some DNA repair genes. Life Sci 166:41–45CrossRefPubMedGoogle Scholar
  13. 13.
    Sanie-Jahromi F, Saadat M (2017) Different profiles of the mRNA levels of DNA repair genes in MCF-7 and SH-SY5Y cells after treatment with combination of cisplatin, 50-Hz electromagnetic field and bleomycin. Biomed Pharmacother 94:564–568CrossRefPubMedGoogle Scholar
  14. 14.
    Luukkonen J, Liimatainen A, Juutilainen J, Naarala J (2014) Induction of genomic instability, oxidative processes, and mitochondrial activity by 50 Hz magnetic fields in human SH-SY5Y neuroblastoma cells. Mutat Res 760:33–41CrossRefPubMedGoogle Scholar
  15. 15.
    El-Bialy NS, Rageh MM (2013) Extremely low-frequency magnetic field enhances the therapeutic efficacy of low-dose cisplatin in the treatment of Ehrlich carcinoma. BioMed Res Int. Google Scholar
  16. 16.
    Tofani S (1999) Physics may help chemistry to improve medicine: a possible mechanism for anticancer activity of static and ELF magnetic fields. Physica Med 15:291–294Google Scholar
  17. 17.
    Flemming K (2010) The use of morphine to treat cancer-related pain: a synthesis of quantitative and qualitative research. J Pain Symptom Manag 39:139–154CrossRefGoogle Scholar
  18. 18.
    Skrabalova J, Drastichova Z, Novotny J (2013) Morphine as a potential oxidative stress-causing agent. Mini-Rev Org Chem 10:367–372CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Saify K, Saadat I, Saadat M (2016) Down-regulation of antioxidant genes in human SH-SY5Y cells after treatment with morphine. Life Sci 144:26–29CrossRefPubMedGoogle Scholar
  20. 20.
    Mahmoudinasab H, Sanie-Jahromi F, Saadat M (2016) Effects of extremely low-frequency electromagnetic field on expression levels of some antioxidant genes in MCF-7 cells. Mol Biol Res Commun 5:77–85PubMedPubMedCentralGoogle Scholar
  21. 21.
    Sebaugh JL (2011) Guidelines for accurate EC50/IC50 estimation. Pharm Stat 10:128–134CrossRefPubMedGoogle Scholar
  22. 22.
    Saify K, Saadat M (2015) Expression patterns of antioxidant genes in human SH-SY5Y cells after treatment with methadone. Psychiatry Res 230:116–119CrossRefPubMedGoogle Scholar
  23. 23.
    Nastiuk KL, Krolewski JJ (2016) Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev 98:35–40CrossRefPubMedGoogle Scholar
  24. 24.
    Pardee AB, Li Y, Li CJ (2002) Cancer therapy with β-lapachone. Curr Cancer Drug Targets 2:227–242CrossRefPubMedGoogle Scholar
  25. 25.
    Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, Misico RI, Arzac GM, Burton G, Bornmann WG, Sutton D (2005) Development of β-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H: quinone oxidoreductase 1 levels. Clin Cancer Res 11:3055–3064CrossRefPubMedGoogle Scholar
  26. 26.
    Cunha-Oliveira T, Silva L, Silva AM, Moreno AJ, Oliveira CR, Santos MS (2013) Acute effects of cocaine, morphine and their combination on bioenergetic function and susceptibility to oxidative stress of rat liver mitochondria. Life Sci 92:1157–1164CrossRefPubMedGoogle Scholar
  27. 27.
    Kovatsi L, Njau S, Nikolaou K, Topouridou K, Papamitsou T, Koliakos G (2010) Evaluation of prooxidant-antioxidant balance in chronic heroin users in a single assay: an identification criterion for antioxidant supplementation. Am J Drug Alcohol Abuse 36:228–232CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Biology, College of SciencesShiraz UniversityShirazIran

Personalised recommendations